Thank you so much for the comment. I love my animals a ton and want to do what I can for them in our hard times ahead.

@Dena Thorp: I just received this froom Dogs Naturally email. I C&V it & will try to share it but mRNA tech 4 latest Rabies Vaccine. mRNA RABIES VACCINES? You may think you’ve heard enough about mRNA vaccines in the last couple of years … but watch out! Soon we may see them for dogs too. Researchers are looking at developing mRNA rabies vaccines … and they’ve been testing them on dogs (and mice). A study into mRNA rabies vaccines by Liverna Therapeutics and the National Institutes for Food and Drug Control in China, as well as Rice University in Texas, was recently published in Virology Journal. MRNA TECHNOLOGY Citing the fact that mRNA technology supports rapid vaccine development on a large scale (sound familiar?) ... the team has developed and tested in vivo a new mRNA-based vaccine against rabies. Injecting viral mRNA into the body is said to provide the cells with the blueprints to create relevant viral proteins. This should trigger an immune response and create antibodies against the disease. POST-EXPOSURE PROTECTION? Because there’s no treatment for rabies, the researchers also wanted to find out whether using mRNA vaccines for post-exposure immunization might be effective. Current post-exposure treatment for humans involves 4-5 doses of inactivated vaccines to provide immunity. Vaccines made from live attenuated viruses might work better, but the live virus is considered too risky. THE STUDY The researchers developed a non-replicating mRNA vaccine using rabies virus G – RABV-G. The test subjects were 6 week old mice and 3 month old dogs. The tests were two-fold: (1) immunization and challenge, and (2) post exposure immunization, where the animals were infected and given the vaccine 6 hours afterwards. Without getting into too much technical detail, here are the main study findings. IMMUNIZATION EXPERIMENTS
 The study showed the Liverna mRNA vaccine effectively induced antibody production and stimulated cellular immune responses, in both mice and dogs. The mice had 100% survival rates after 2 doses. Survival rates were much lower in mice who had only one dose: 77.8% or 55.6% depending on the dose size. Dogs who had 2 or 3 doses produced protective antibody levels, and survival rates were 100% at 3 months post-infection. Neutralizing antibodies were as high or higher than a traditional inactivated vaccine. POST EXPOSURE EXPERIMENTS In the post-exposure experiments, the Liverna vaccine had an 80% survival rate. This compared favorably with inactivated vaccine results where most dogs died within 14 days … before the full 5-dose immunization program was completed. However, the dogs were infected with a different rabies strain than the strain in the inactivated vaccine … so this may have weakened the results. STUDY CONCLUSIONS The researchers concluded that immunization with two doses of an mRNA vaccine can achieve equal or better efficacy in mice and dogs than the normal inactivated rabies vaccines. They observed no adverse clinical effects … but as we know, it’s not unusual to see vaccine adverse effects in dogs months or even years after vaccination. The dogs were only observed for 3 months in this study. COULD THIS HAPPEN? It seems likely that research into mRNA vaccines against rabies will continue … in humans as well as animals. There's a profit incentive, for one thing. The researchers noted that large-scale production of mRNA vaccines is less time-consuming (ie cheaper) and more effective than inactivated vaccines. And it’s not surprising to note that the Liverna mRNA vaccine used in this study has been patented (in China). An effective post exposure vaccine for rabies could be a useful tool. But we’re not holding our breath … especially given what we’ve seen of mRNA vaccine efficacy and safety in recent history. The long term side effects are potentially very harmful (as you'll know if you read alternative media sources) … and information about those is still emerging.  mRNA RABIES VACCINES? You may think you’ve heard enough about mRNA vaccines in the last couple of years … but watch out! Soon we may see them for dogs too. Researchers are looking at developing mRNA rabies vaccines … and they’ve been testing them on dogs (and mice). A study into mRNA rabies vaccines by Liverna Therapeutics and the National Institutes for Food and Drug Control in China, as well as Rice University in Texas, was recently published in Virology Journal. MRNA TECHNOLOGY Citing the fact that mRNA technology supports rapid vaccine development on a large scale (sound familiar?) ... the team has developed and tested in vivo a new mRNA-based vaccine against rabies. Injecting viral mRNA into the body is said to provide the cells with the blueprints to create relevant viral proteins. This should trigger an immune response and create antibodies against the disease. POST-EXPOSURE PROTECTION? Because there’s no treatment for rabies, the researchers also wanted to find out whether using mRNA vaccines for post-exposure immunization might be effective. Current post-exposure treatment for humans involves 4-5 doses of inactivated vaccines to provide immunity. Vaccines made from live attenuated viruses might work better, but the live virus is considered too risky. THE STUDY The researchers developed a non-replicating mRNA vaccine using rabies virus G – RABV-G. The test subjects were 6 week old mice and 3 month old dogs. The tests were two-fold: (1) immunization and challenge, and (2) post exposure immunization, where the animals were infected and given the vaccine 6 hours afterwards. Without getting into too much technical detail, here are the main study findings. IMMUNIZATION EXPERIMENTS
 The study showed the Liverna mRNA vaccine effectively induced antibody production and stimulated cellular immune responses, in both mice and dogs. The mice had 100% survival rates after 2 doses. Survival rates were much lower in mice who had only one dose: 77.8% or 55.6% depending on the dose size. Dogs who had 2 or 3 doses produced protective antibody levels, and survival rates were 100% at 3 months post-infection. Neutralizing antibodies were as high or higher than a traditional inactivated vaccine. POST EXPOSURE EXPERIMENTS In the post-exposure experiments, the Liverna vaccine had an 80% survival rate. This compared favorably with inactivated vaccine results where most dogs died within 14 days … before the full 5-dose immunization program was completed. However, the dogs were infected with a different rabies strain than the strain in the inactivated vaccine … so this may have weakened the results. STUDY CONCLUSIONS The researchers concluded that immunization with two doses of an mRNA vaccine can achieve equal or better efficacy in mice and dogs than the normal inactivated rabies vaccines. They observed no adverse clinical effects … but as we know, it’s not unusual to see vaccine adverse effects in dogs months or even years after vaccination. The dogs were only observed for 3 months in this study. COULD THIS HAPPEN? It seems likely that research into mRNA vaccines against rabies will continue … in humans as well as animals. There's a profit incentive, for one thing. The researchers noted that large-scale production of mRNA vaccines is less time-consuming (ie cheaper) and more effective than inactivated vaccines. And it’s not surprising to note that the Liverna mRNA vaccine used in this study has been patented (in China). An effective post exposure vaccine for rabies could be a useful tool. But we’re not holding our breath … especially given what we’ve seen of mRNA vaccine efficacy and safety in recent history. The long term side effects are potentially very harmful (as you'll know if you read alternative media sources) … and information about those is still emerging.